0QV2 Stock Chart & Stats
kr16.20
kr12.00(19.35%)
At close: 4:00 PM EST
kr16.20
kr12.00(19.35%)
Day’s Range― - ―
52-Week Rangekr15.00 - kr17.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
kr560.70M
Enterprise Valuekr648.89M
Total Cash (Recent Filing)kr55.05M
Total Debt (Recent Filing)kr153.75M
Price to Earnings (P/E)88.9
Beta0.10
Next Earnings
Feb 04, 2027EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend Yield0.25%
Share Statistics
EPS (TTM)0.18
Shares Outstanding31,043,884
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)2.21
Price to Sales (P/S)3.23
P/FCF Ratio-96.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.21
Revenue Forecast (FY)kr215.82M
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationThe return to positive operating and free cash flow strengthens internal funding capacity and reduces reliance on external financing. If maintained, better cash conversion can support product development, partner implementation, and regulatory activity while providing greater resilience through normal business fluctuations.
Moderate LeverageModerate and improving leverage, together with a sizable equity base, gives Bactiguard meaningful financial flexibility. This supports continued investment in its infection-prevention platform and partnerships while reducing the balance-sheet pressure that can constrain smaller medical-technology companies.
Proprietary Scalable TechnologyBactiguard’s proprietary coating platform can reach healthcare markets through manufacturer collaborations rather than relying only on direct product sales. Broader partner adoption could create scalable license and royalty opportunities while embedding infection-prevention technology into established device distribution channels.
Bears Say
Unproven ProfitabilityDespite substantial improvement from earlier losses, the company has not yet demonstrated durable operating profitability or positive shareholder returns. Continued losses could limit internally funded growth, weaken confidence in the business model, and make results more sensitive to execution and adoption timing.
Volatile Cash ConversionThe recent cash-flow improvement is encouraging, but large historical swings make it difficult to treat current generation as dependable. Inconsistent conversion can complicate investment planning and leave less certainty about the cash available for commercialization, partnerships, and ongoing operations.
Limited Revenue MomentumRevenue growth remains relatively modest for a company seeking wider adoption of infection-prevention technology. Slower top-line expansion may delay operating leverage and the path to sustainable profit, particularly because commercialization depends on partner uptake, device sales, and healthcare procurement decisions.
Bactiguard Holding AB News
0QV2 FAQ
What was Bactiguard Holding AB’s price range in the past 12 months?
Bactiguard Holding AB lowest share price was kr15.00 and its highest was kr17.25 in the past 12 months.
What is Bactiguard Holding AB’s market cap?
Bactiguard Holding AB’s market cap is kr560.70M.
When is Bactiguard Holding AB’s upcoming earnings report date?
Bactiguard Holding AB’s upcoming earnings report date is Feb 04, 2027 which is in 95 days.
How were Bactiguard Holding AB’s earnings last quarter?
Bactiguard Holding AB released its earnings results on Oct 22, 2026. The company reported kr0.3 earnings per share for the quarter, beating the consensus estimate of -kr0.2 by kr0.5.
Is Bactiguard Holding AB overvalued?
According to Wall Street analysts Bactiguard Holding AB’s price is currently Overvalued.
Does Bactiguard Holding AB pay dividends?
Bactiguard Holding AB pays a Notavailable dividend of kr0.285 which represents an annual dividend yield of 0.25%. See more information on Bactiguard Holding AB dividends here
What is Bactiguard Holding AB’s EPS estimate?
Bactiguard Holding AB’s EPS estimate is -0.1.
How many shares outstanding does Bactiguard Holding AB have?
Bactiguard Holding AB has 31,043,884 shares outstanding.
What happened to Bactiguard Holding AB’s price movement after its last earnings report?
Bactiguard Holding AB reported an EPS of kr0.3 in its last earnings report, beating expectations of -kr0.2. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bactiguard Holding AB?
Currently, no hedge funds are holding shares in GB:0QV2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bactiguard Holding AB
Bactiguard Holding AB (publ), a Swedish-based global medical technology company, specializes in developing and supplying innovative solutions designed to prevent infections. Its primary objective is to mitigate healthcare-associated infections (HAIs) and reduce the global dependency on antibiotics. The core of Bactiguard's product line, known as Bactiguard Infection Protection (BIP), encompasses a range of coated medical devices. This includes various urinary catheters, such as the BIP Foley Catheter and the temperature-sensing BIP Foley TempSensor, all engineered to inhibit microbial adhesion and prevent urinary tract infections. Similarly, the BIP Central Venous Catheter and BIP Endotracheal Tube (with the BIP Endotracheal Tube Evac variant offering subglottic secretion drainage) work to reduce the risk of bloodstream and respiratory tract infections by minimizing biofilm formation. Beyond its BIP portfolio, the company offers a diverse array of other products, including Hydrocyn aqua advanced wound care for cleaning and debriding acute, chronic, and infected wounds, as well as general Bactiguard Wound Care items. It also provides a comprehensive selection of surgical sutures (natural absorbable, synthetic absorbable, non-absorbable, and specialty types), VigiMesh for hernia repair, and Hydrocyn aqua advanced disinfectant for sanitizing skin and surfaces. Additionally, Bactiguard supplies specialized orthopedic trauma implants featuring infection prevention technology under the ZNN Bactiguard brand, and the Aniocyn line of wound and skin care products for various pets. Bactiguard Holding AB (publ) was established in 2005 and maintains its headquarters in Tullinge, Sweden.